Bostwick Laboratories opens new facility in Nashville

"It is the right time and I have been fortunate to have such great people to work with locally and nationally," a urologist writes.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

The findings suggest that drug therapies targeting the NOTCH1 gene may serve as an alternative treatment option for patients with kidney cancer in whom surgery is not recommended.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

In the first article of this series, Naveen Kella, MD, discusses the transformative impact of PSMA PET-CT imaging on prostate cancer diagnosis, highlighting its advantages and addressing clinical challenges and guidelines in this evolving field.

The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.